Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6390 plus aromatase inhibitor versus placebo plus aromatase inhibitor in HR-positive, HER2-negative advanced breast cancer
CTR20190962Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalpiciclib in breast cancer, sponsored by Hengrui Therapeutics. Started Jul 2019; status: active.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20190962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190962.